Durvalumab is a fully human monoclonal antibody developed by AstraZeneca that targets programmed death-ligand 1 (PD-L1), a critical immune checkpoint protein expressed on tumor and antigen-presenting cells [213,214]. Here, CD274 is linked to neoplasm.